A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma.

Trial Profile

A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Vorinostat (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MUK four
  • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 16).
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005361-20).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top